662 related articles for article (PubMed ID: 24135129)
1. Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia.
Bézard E; Muñoz A; Tronci E; Pioli EY; Li Q; Porras G; Björklund A; Carta M
Neurosci Res; 2013 Dec; 77(4):242-6. PubMed ID: 24135129
[TBL] [Abstract][Full Text] [Related]
2. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
3. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
[TBL] [Abstract][Full Text] [Related]
4. NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
Iderberg H; McCreary AC; Varney MA; Kleven MS; Koek W; Bardin L; Depoortère R; Cenci MA; Newman-Tancredi A
Exp Neurol; 2015 Sep; 271():335-50. PubMed ID: 26037043
[TBL] [Abstract][Full Text] [Related]
5. Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action.
Iderberg H; Rylander D; Bimpisidis Z; Cenci MA
Exp Neurol; 2013 Dec; 250():116-24. PubMed ID: 24029003
[TBL] [Abstract][Full Text] [Related]
6. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
Bezard E; Tronci E; Pioli EY; Li Q; Porras G; Björklund A; Carta M
Mov Disord; 2013 Jul; 28(8):1088-96. PubMed ID: 23389842
[TBL] [Abstract][Full Text] [Related]
7. Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
Pinna A; Ko WK; Costa G; Tronci E; Fidalgo C; Simola N; Li Q; Tabrizi MA; Bezard E; Carta M; Morelli M
Mov Disord; 2016 Apr; 31(4):501-11. PubMed ID: 26871939
[TBL] [Abstract][Full Text] [Related]
8. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
Iderberg H; McCreary AC; Varney MA; Cenci MA; Newman-Tancredi A
Neuropharmacology; 2015 Jun; 93():52-67. PubMed ID: 25645393
[TBL] [Abstract][Full Text] [Related]
9. The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.
Shin E; Lisci C; Tronci E; Fidalgo C; Stancampiano R; Björklund A; Carta M
Neurobiol Dis; 2014 Feb; 62():233-40. PubMed ID: 24135006
[TBL] [Abstract][Full Text] [Related]
10. The selective 5-HT
Fisher R; Hikima A; Morris R; Jackson MJ; Rose S; Varney MA; Depoortere R; Newman-Tancredi A
Neuropharmacology; 2020 May; 167():107997. PubMed ID: 32057799
[TBL] [Abstract][Full Text] [Related]
11. Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Fidalgo C; Ko WK; Tronci E; Li Q; Stancampiano R; Chuan Q; Bezard E; Carta M
Neuroscience; 2015 Jul; 298():389-96. PubMed ID: 25907446
[TBL] [Abstract][Full Text] [Related]
12. The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque.
Huot P; Johnston TH; Fox SH; Newman-Tancredi A; Brotchie JM
Neuropharmacology; 2015 Oct; 97():306-11. PubMed ID: 26071982
[TBL] [Abstract][Full Text] [Related]
13. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
[TBL] [Abstract][Full Text] [Related]
14. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
Grégoire L; Samadi P; Graham J; Bédard PJ; Bartoszyk GD; Di Paolo T
Parkinsonism Relat Disord; 2009 Jul; 15(6):445-52. PubMed ID: 19196540
[TBL] [Abstract][Full Text] [Related]
15. Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys.
Morissette M; Samadi P; Hadj Tahar A; Bélanger N; Di Paolo T
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr; 34(3):446-54. PubMed ID: 20026151
[TBL] [Abstract][Full Text] [Related]
16. The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.
McCreary AC; Varney MA; Newman-Tancredi A
Neuropharmacology; 2016 Jun; 105():651-660. PubMed ID: 26777281
[TBL] [Abstract][Full Text] [Related]
17. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM
Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
[TBL] [Abstract][Full Text] [Related]
18. Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia.
Riahi G; Morissette M; Samadi P; Parent M; Di Paolo T
Biochem Pharmacol; 2013 Oct; 86(7):970-8. PubMed ID: 23954709
[TBL] [Abstract][Full Text] [Related]
19. The selective 5-HT
Depoortere R; Johnston TH; Fox SH; Brotchie JM; Newman-Tancredi A
Parkinsonism Relat Disord; 2020 Sep; 78():151-157. PubMed ID: 32846366
[TBL] [Abstract][Full Text] [Related]
20. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
Tamim MK; Samadi P; Morissette M; Grégoire L; Ouattara B; Lévesque D; Rouillard C; Di Paolo T
Neuropharmacology; 2010 Jan; 58(1):286-96. PubMed ID: 19576910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
